Neurothrombectomy Devices Market By Product Type (Clot Retrievers, Vascular Snares, Aspiration/Suction Devices, Others); By Technique (Mechanical Thrombectomy, Aspiration Thrombectomy, Combined Techniques); By End User (Hospitals, Ambulatory Surgical Centers [ASCs], Others); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Neurothrombectomy Devices Market: Advanced Clot Retrieval Technologies Transform Acute Ischemic Stroke Intervention

The Global Neurothrombectomy Devices Market is projected to grow from USD 825 million in 2025 to USD 1.33 billion by 2032, registering a CAGR of 7.1% during 2026–2032.

 

Neurothrombectomy devices are minimally invasive tools used to remove or break blood clots in brain arteries during an ischemic stroke, quickly restoring blood flow and reducing brain damage. The main types include stent retrievers, which are mesh-based devices designed to trap and extract clots; aspiration systems, which use vacuum-assisted catheters to suction out the blockage; laser or ultrasound-based tools, which are emerging technologies that help fragment clots to facilitate removal; and snares, which are small loop devices used to capture and retrieve obstructing material from the vessel. These devices offer key clinical benefits such as faster restoration of cerebral blood flow, the ability to treat selected patients up to 24 hours after stroke onset, and reduced dependence on systemic clot-dissolving drugs, which in turn lowers the risk of bleeding complications.

 

FDA-approved neurothrombectomy devices for acute ischemic stroke include stent retrievers, aspiration systems, and computer-assisted vacuum platforms, all designed to improve clot removal efficiency in patients with large vessel occlusions. Stent retrievers are mesh-based devices that capture and extract clots, with key examples including Medtronic Solitaire, Stryker Trevo, and Rapid Medical Tigertriever, including the Tigertriever 25 variant used in high clot burden cases. Aspiration systems rely on vacuum-based catheters to suction and remove thrombi, with widely used products such as Penumbra’s RED system and MicroVention’s SOFIA series. Computer-assisted vacuum thrombectomy platforms, such as Penumbra’s Thunderbolt, use automated suction control to optimize clot engagement and improve first-pass success rates. Alongside these approved technologies, emerging innovations are expanding the field, including robotic and remote thrombectomy systems like Sentante that aim to enable procedures in hospitals without on-site specialists, force-controlled expandable devices that allow real-time adjustment of stent or net expansion for safer navigation in complex cerebral vessels, and AI-driven aspiration systems that automatically regulate suction intensity based on clot location and resistance to enhance procedural precision and outcomes.

 

How Large Is the Patient and Procedure Base for Neurothrombectomy Devices?

More than 795,000 strokes occur annually in the United States, and approximately 87% are ischemic. A U.S. population model estimated around 718,191 acute ischemic strokes annually, including approximately 80,075 large-vessel occlusions (LVOs) and 65,798 medium-vessel occlusions (MVOs). Together, LVO and MVO events were estimated at 145,873 annually.

Actual procedure volumes show how this patient pool converts into device demand. U.S. mechanical thrombectomy volume was estimated at 39,164 procedures in 2021, increasing to approximately 43,015 cases in 2022. Globally, approximately 200,000 mechanical thrombectomy procedures were performed in 2020, compared with fewer than 100,000 in 2016.

Global ischemic-stroke incidence was approximately 7.8 million cases in 2021. Using a published LVO range of 10–20% indicates a potential worldwide LVO pool of approximately 0.78 million to 1.56 million events annually. The gap between the underlying disease population and current thrombectomy volumes supports further procedure penetration as access improves.

 

Which Product Types Are Driving the Neurothrombectomy Devices Market?

Clot Retrievers

Clot retrievers accounted for an estimated 43.5% of the Neurothrombectomy Devices Market in 2025, equivalent to approximately $358.9 million, and are projected to grow at a CAGR of 6.2% during 2026–2032. Stent retrievers remain widely used for physically capturing and removing thrombus during LVO procedures, with Stryker's Trevo and Medtronic's Solitaire among the established platforms.

Clinical utilization supports the segment's large position. A nationwide registry of 3,309 thrombectomy patients found that 1,990 patients, or 60.1%, received stent-retriever-based thrombectomy as the first-line approach. Continued growth in U.S. thrombectomy volumes supports recurring demand for single-use retrievers.

Vascular Snares

Vascular snares represented an estimated 4.2% market share in 2025, valued at approximately $34.7 million, and are projected to expand at a CAGR of 5.1% through 2032. Their role is more specialized than stent retrievers or aspiration systems and is concentrated in selected complex neurovascular retrieval situations.

Demand therefore follows growth in difficult neurointerventional cases rather than overall thrombectomy volume directly. The approximately 43,015 U.S. thrombectomy cases reported in 2022 provide a growing procedural base within which specialized retrieval tools can be required.

Aspiration/Suction Devices

Aspiration/suction devices accounted for an estimated 38.7% of the market in 2025, equal to approximately $319.3 million, and are expected to record the fastest product-type CAGR of 7.8% during 2026–2032. Growth is being supported by wider adoption of large-bore reperfusion catheters and increased investment in vacuum-assisted clot removal.

Penumbra's THUNDER study included 216 patients across 29 U.S. centers, while THUNDERBOLT received FDA clearance in 2026. Penumbra also reported $947.9 million in global thrombectomy-product revenue in 2025, up 16.2% year over year, illustrating strong commercial momentum across its wider clot-removal portfolio.

Others

Other neurothrombectomy products held an estimated 13.6% market share in 2025, corresponding to approximately $112.2 million, and are projected to grow at a CAGR of 6.2% through 2032. This category includes guide catheters, support catheters, delivery devices, and other vascular-access products needed to reach and treat the cerebral occlusion.

Johnson & Johnson expanded its CEREGLIDE portfolio with additional catheter products, while Terumo Neuro has strengthened its position through the SOFIA platform. Because one thrombectomy can require several access and support devices, procedure growth creates recurring demand beyond the primary clot-removal product.

 

Which Techniques Are Most Important in Neurothrombectomy?

Mechanical Thrombectomy

Mechanical thrombectomy using stent-retriever-led approaches accounted for an estimated 34.8% of market revenue in 2025, valued at approximately $287.1 million, and is projected to grow at a CAGR of 6.0% during 2026–2032. It remains a well-established approach for treating acute ischemic stroke caused by LVO.

U.S. thrombectomy activity increased from 39,164 procedures in 2021 to approximately 43,015 cases in 2022, supporting continued consumption of retrieval and supporting access devices.

Aspiration Thrombectomy

Aspiration thrombectomy represented an estimated 21.0% share in 2025, equal to approximately $173.3 million, and is projected to expand at a CAGR of 7.4% through 2032. Increasing physician use of direct aspiration and continued investment in catheter technology are supporting above-market growth.

Real-world evidence also shows meaningful utilization. In a nationwide Swedish registry of 3,309 patients, 1,319 received aspiration-based thrombectomy as the first-line technique. New systems from Penumbra, Imperative Care, Terumo, and other companies continue to increase competition in aspiration-led treatment.

Combined Techniques

Combined techniques accounted for an estimated 44.2% of the market in 2025, representing approximately $364.7 million, and are projected to grow at a CAGR of 7.3% during 2026–2032. Their larger revenue contribution reflects the use of aspiration and stent-retriever products within the same procedure, increasing device consumption per case.

The international INSPIRE-S registry enrolled 802 patients across 29 sites in 13 countries: 397 patients, or 49.5%, received combination therapy, compared with 259 receiving stent retrievers alone and 146 receiving aspiration alone. The ASTER2 randomized trial also included 408 patients and reported near-total or complete reperfusion in 64.5% with combined therapy versus 57.9% with stent retriever alone.

 

Which End Users Generate the Most Neurothrombectomy Device Demand?

Hospitals

Hospitals accounted for an estimated 90.5% of the Neurothrombectomy Devices Market in 2025, equivalent to approximately $746.6 million, and are projected to grow at a CAGR of 6.7% through 2032. Comprehensive stroke centers and thrombectomy-capable hospitals dominate demand because treatment requires emergency imaging, neurointerventional specialists, anesthesia and critical-care support, and endovascular facilities.

The approximately 43,015 U.S. thrombectomy cases recorded in 2022 illustrate the concentration of demand within hospital stroke pathways. High-volume hospitals also generate repeated demand for retrievers, aspiration catheters, and vascular-access products.

Ambulatory Surgical Centers (ASCs)

Ambulatory Surgical Centers accounted for an estimated 2.4% market share in 2025, valued at approximately $19.8 million, and are projected to grow at a CAGR of 5.0% during 2026–2032. Their role remains limited because emergency thrombectomy requires hospital-level stroke diagnosis, imaging, intensive monitoring, and immediate specialist support.

ASCs therefore represent a considerably smaller commercial channel than comprehensive stroke centers and tertiary hospitals, with most acute thrombectomy activity continuing to occur in hospital-based neurointerventional facilities.

Others

Other end users represented an estimated 7.1% of the market in 2025, corresponding to approximately $58.6 million, and are projected to record the fastest end-user CAGR of 8.4% through 2032. This segment includes academic medical centers, research institutions, and specialized neurovascular facilities involved in physician training and clinical evaluation of emerging technologies.

Penumbra's FORWARD study plans to enroll up to 250 patients at approximately 40 sites to evaluate thrombectomy in distal M2 stroke, illustrating the importance of academic and research centers in expanding future device indications.

 

Which Regions Offer the Strongest Neurothrombectomy Device Opportunities?

North America

North America accounted for an estimated 41.5% of the global Neurothrombectomy Devices Market in 2025, valued at approximately $342.4 million, and is projected to grow at a CAGR of 6.1% through 2032. The region benefits from established stroke-center networks, high procedure volumes, neurointerventional expertise, and frequent product launches.

The United States has approximately 80,075 modeled LVO events annually, compared with around 43,015 thrombectomy cases in 2022, leaving room for further treatment penetration.

Europe

Europe represented an estimated 28.2% market share in 2025, equivalent to approximately $232.7 million, and is projected to expand at a CAGR of 6.4% through 2032. Established stroke networks support device demand, although treatment access remains uneven.

The 2023 Stroke Service Tracker covered 47 European countries and found EVT treatment proportions ranging from 0.2% to 14.3%, demonstrating substantial differences in thrombectomy penetration. Greater access in lower-penetration countries creates room for procedure and device growth.

Asia-Pacific

Asia-Pacific accounted for an estimated 24.3% of the market in 2025, valued at approximately $200.5 million, and is projected to record the fastest regional CAGR of 8.3% during 2026–2032. The region combines a large stroke burden with expanding neurointerventional infrastructure and significant unmet access.

China's stroke surveillance system collected data on 49,845 mechanical thrombectomy patients during 2019–2020. In India, 361 EVT-capable centers were identified, while only 20.6% of the population could reach an EVT-capable center within one hour, leaving substantial potential for infrastructure-led expansion.

Latin America, Middle East and Africa

Latin America, the Middle East and Africa together represented an estimated 6.0% market share in 2025, equal to approximately $49.5 million, and are projected to grow at a CAGR of 7.2% through 2032. Demand remains concentrated in tertiary hospitals and major urban neurointerventional centers.

Global evidence shows that access remains a major constraint: published stroke-service data identified endovascular thrombectomy services in only 33 countries within the reviewed global evidence base, with most represented countries classified as high income. Expansion of specialist training and EVT-capable centers is therefore central to regional market development.

 

Which Companies Are Shaping the Neurothrombectomy Devices Market?

Penumbra, Stryker, Medtronic, Johnson & Johnson MedTech/CERENOVUS, Terumo Neuro, and Imperative Care are prominent participants across clot retrieval, aspiration, and neurovascular access.

Penumbra is strongly positioned in aspiration thrombectomy through the RED catheter family and THUNDERBOLT computer-assisted vacuum thrombectomy platform. Stryker competes through Trevo NXT and related neurovascular devices, while Medtronic maintains an established presence through Solitaire X.

Johnson & Johnson MedTech/CERENOVUS combines EMBOTRAP clot retrieval with the CEREGLIDE catheter family. Terumo Neuro participates through SOFIA aspiration and access products, while Imperative Care is building an integrated stroke franchise around the Zoom Stroke System.

Competition is increasingly shifting from individual devices toward broader procedural platforms. Companies capable of supplying aspiration catheters, clot retrievers, and vascular-access devices can capture a larger portion of spending generated by each thrombectomy procedure.

 

What Will Drive the Neurothrombectomy Devices Market Through 2032?

Future growth will depend on converting a larger proportion of eligible ischemic stroke patients into thrombectomy procedures. The United States has approximately 80,075 modeled annual LVO events compared with around 43,015 thrombectomy cases in 2022, while international treatment access remains considerably more uneven.

Aspiration/suction devices are expected to record the strongest product-type growth at an estimated 7.8% CAGR, while combined techniques are positioned strongly with an estimated 44.2% 2025 share. Hospitals will remain the dominant purchasing channel, while Asia-Pacific is projected to be the fastest-growing regional market at 8.3% CAGR.

Higher procedure penetration, expansion of EVT-capable hospitals, broader clinical eligibility, and competition across integrated aspiration, retrieval, and access platforms support the projected increase of the global neurothrombectomy devices market from $825 million in 2025 to $1.33 billion by 2032, registering a CAGR of 7.1% during 2026–2032.

 

Neurothrombectomy Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 825 Million
Revenue Forecast in 2032	USD 1.33 Billion
Overall Growth Rate	CAGR of 7.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Technique, By End User, By Geography
By Product Type	Clot Retrievers, Vascular Snares, Aspiration/Suction Devices, Others
By Technique	Mechanical Thrombectomy, Aspiration Thrombectomy, Combined Techniques
By End User	Hospitals, Ambulatory Surgical Centers [ASCs], Others
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising incidence of ischemic stroke and large-vessel occlusion, increasing penetration of mechanical thrombectomy procedures, expansion of EVT-capable stroke centers, growing adoption of aspiration and combined thrombectomy techniques, and continued innovation in computer-assisted clot retrieval systems
Customization Option	Available upon request